Skip to main content

Find a clinical trial

AC-061A302

A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile associated diarrhea (CDAD) Mickael Aoun

AMC303-01

A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Philippe Aftimos

OLYMPIA D081CC00006 BIG 6-13, NSABP B-55

A randomised, double-blind, parallel group, placebo-controlled multicentre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy (OLYMPIA study) Daphné Tkint de Roodenbeke

PALLAS

PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer Michail Ignatiadis

BAY 88-8223 / 17096

A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus when administered to metastatic HER2 negative hormone receptor positive breast cancer subjets with bone metastases Michael Gebhart

AURORA

BIG 14-01 AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer Philippe Aftimos

CA209358 / CheckMate 358

Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors. Ahmad Hussein Awada

1367.1

An open label, Phase Ia/Ib dose finding study with BI 894999 orally administeredonce a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Ahmad Hussein Awada

BSMO 2014 01

A prospective, Belgian multi-center, single-arm, phase II study of neoadjuvant weekly paclitaxel and carboplatin followed by dose dense epirubicin and cyclophosphamide in stage II and III triple negative breast cancer Daphné Tkint de Roodenbeke

IJB_2706

An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors Christiane Jungels

STRIVE

a phase 2, multicenter, randomized, double-blind study of the safety, tolerability and efficacy of intravenous CD101 vs intravenous caspofungin followed by oral fluconazole stept-down in the treatment of subjects with candidemia Mickael Aoun

EORTC 1658

Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) Konstantinos Stathopoulos

EORTC 10085p MALE BREAST

EORTC 10085p MALE BREAST Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG, TBCRC and NABCG intergroup study Lissandra Dal Lago

G1T48-01

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 in Women with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer (G1T48-01) Philippe Aftimos

GO29674

A phase Ib, open-label, dose-escalation study of the safety and Pharmacokinetics of MOXR0916 and MPDL3280A in patients with locally advanced or metastatic solid tumors Ahmad Hussein Awada

MONALEESA-7

A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer Andrea Gombos

ODO-TE-B301, CONTESSA

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Women with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane Andrea Gombos

OX2016-203-01

An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors Nuria Kotecki

IJB_2672

A Phase 3, Placebo-controlled, randomized, oserved-blindedstudy to evaluate the efficacy, safety, and tolerability of a Clostridium Difficile Vaccine in adults 50 years of age and older. Mickael Aoun

WO29522

A Phase III, MULTICENTER, RANDOMIZED, placebo-controlled Study OF MPDL3280A (Anti-PD-L1 Antibody) IN COMBINATION WITH NAB-PACLITAXEL COMPARED with placebo with NAB-PACLITAXEL for PATIENTS WITH previously UNtreated metastatic TRIPLE-NEGATIVE BREAST CANCER Andrea Gombos